handshake-1
miodrag ignjatovic / iStockphoto.com
31 January 2018Americas

Celgene reaches settlement with Actavis

Biopharmaceutical company Celgene has reached an agreement with Actavis that will terminate pending patent litigation over Abraxane (paclitaxel protein-bound particles for injectable suspension).

Abraxane is a chemotherapy drug that is used to treat breast cancer that has spread to other parts of the body. It can also be used to treat pancreatic cancer and certain types of lung cancer.

US patent numbers covering Abraxane include 7,758,891; 7,820,788; and 7,923,536. The patents are assigned to Abraxis BioScience, a company acquired by Celgene in 2010.

The settlement, which was announced on Friday, January 26, will see the parties file a consent judgment with the US District Court for the District of New Jersey to enjoin Actavis from selling a generic version of Abraxane until the patents expire. An inter partes review will also be terminated.

Celgene has provided Actavis with a licence to the patents from March 31, 2022.

In September 2016, LSIPR reported that India-based pharmaceutical company Glenmark had signed a drug agreement with Particle Sciences, a provider of drug development services, to develop, license and commercialise a generic version of Abraxane.

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories like this sent straight to your inbox.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
27 September 2016   India-based pharmaceutical company Glenmark has signed a wide-ranging drug agreement with Particle Sciences, a provider of drug development services.

More on this story

Americas
27 September 2016   India-based pharmaceutical company Glenmark has signed a wide-ranging drug agreement with Particle Sciences, a provider of drug development services.

More on this story

Americas
27 September 2016   India-based pharmaceutical company Glenmark has signed a wide-ranging drug agreement with Particle Sciences, a provider of drug development services.